BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 31385766)

  • 1. Association Between CYP3A4 and CYP3A5 Genotypes and Cyclosporine's Blood Levels and Doses among Jordanian Kidney Transplanted Patients.
    El-Shair S; Al Shhab M; Zayed K; Alsmady M; Zihlif M
    Curr Drug Metab; 2019; 20(8):682-694. PubMed ID: 31385766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP3A4/5 polymorphisms affect the blood level of cyclosporine and tacrolimus in Chinese renal transplant recipients.
    Li DY; Teng RC; Zhu HJ; Fang Y
    Int J Clin Pharmacol Ther; 2013 Jun; 51(6):466-74. PubMed ID: 23557867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients.
    Lunde I; Bremer S; Midtvedt K; Mohebi B; Dahl M; Bergan S; Åsberg A; Christensen H
    Eur J Clin Pharmacol; 2014 Jun; 70(6):685-93. PubMed ID: 24658827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of CYP3A4*1B and CYP3A5*3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients.
    Żochowska D; Wyzgał J; Pączek L
    Ann Transplant; 2012; 17(3):36-44. PubMed ID: 23018254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphisms in CYP3A5, CYP3A4, and ABCB1 are not associated with cyclosporine pharmacokinetics nor with cyclosporine clinical end points after renal transplantation.
    Bouamar R; Hesselink DA; van Schaik RH; Weimar W; Macphee IA; de Fijter JW; van Gelder T
    Ther Drug Monit; 2011 Apr; 33(2):178-84. PubMed ID: 21383650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequencies and roles of CYP3A5, CYP3A4 and ABCB1 single nucleotide polymorphisms in Italian teenagers after kidney transplantation.
    Turolo S; Tirelli AS; Ferraresso M; Ghio L; Belingheri M; Groppali E; Torresani E; Edefonti A
    Pharmacol Rep; 2010; 62(6):1159-69. PubMed ID: 21273673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYP3A4∗18B and CYP3A5∗3 polymorphisms contribute to pharmacokinetic variability of cyclosporine among healthy Chinese subjects.
    Tao XR; Xia XY; Zhang J; Tong LY; Zhang W; Zhou X; Liu ZH; Song HT
    Eur J Pharm Sci; 2015 Aug; 76():238-44. PubMed ID: 25976223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation.
    Hu YF; Qiu W; Liu ZQ; Zhu LJ; Liu ZQ; Tu JH; Wang D; Li Z; He J; Zhong GP; Zhou G; Zhou HH
    Clin Exp Pharmacol Physiol; 2006 Nov; 33(11):1093-8. PubMed ID: 17042920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Genetic Polymorphism in CYP3A4 and CYP3A5 Genes on Tacrolimus Dose Among Kidney Transplant Recipients.
    Yousef AM; Qosa H; Bulatova N; Abuhaliema A; Almadhoun H; Khayyat G; Olemat M
    Iran J Kidney Dis; 2016 May; 10(3):156-63. PubMed ID: 27225724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Age and Allele Variants of CYP3A5, CYP3A4, and POR Genes on the Pharmacokinetics of Cyclosporin A in Pediatric Renal Transplant Recipients From Serbia.
    Cvetković M; Zivković M; Bundalo M; Gojković I; Spasojević-Dimitrijeva B; Stanković A; Kostić M
    Ther Drug Monit; 2017 Dec; 39(6):589-595. PubMed ID: 29135906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients.
    Crettol S; Venetz JP; Fontana M; Aubert JD; Pascual M; Eap CB
    Ther Drug Monit; 2008 Dec; 30(6):689-99. PubMed ID: 18978522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients.
    Qiu XY; Jiao Z; Zhang M; Zhong LJ; Liang HQ; Ma CL; Zhang L; Zhong MK
    Eur J Clin Pharmacol; 2008 Nov; 64(11):1069-84. PubMed ID: 18636247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of CYP3A polymorphisms with the pharmacokinetics of cyclosporine A in early post-renal transplant recipients in China.
    Meng XG; Guo CX; Feng GQ; Zhao YC; Zhou BT; Han JL; Chen X; Shi Y; Shi HY; Yin JY; Peng XD; Pei Q; Zhang W; Wang G; He M; Liu M; Yang JK; Zhou HH
    Acta Pharmacol Sin; 2012 Dec; 33(12):1563-70. PubMed ID: 23085740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of combined CYP3A4 and CYP3A5 single-nucleotide polymorphisms on tacrolimus exposure in kidney transplant recipients: a study according to the post-transplant phase.
    Aouam K; Kolsi A; Kerkeni E; Ben Fredj N; Chaabane A; Monastiri K; Boughattas N
    Pharmacogenomics; 2015 Dec; 16(18):2045-54. PubMed ID: 26615671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of ABCB1, CYP3A4*18B and CYP3A5*3 polymorphisms on cyclosporine A pharmacokinetics in bone marrow transplant recipients.
    Qiu F; He XJ; Sun YX; Li-Ling J; Zhao LM
    Pharmacol Rep; 2011; 63(3):815-25. PubMed ID: 21857093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis.
    Zuo XC; Ng CM; Barrett JS; Luo AJ; Zhang BK; Deng CH; Xi LY; Cheng K; Ming YZ; Yang GP; Pei Q; Zhu LJ; Yuan H; Liao HQ; Ding JJ; Wu D; Zhou YN; Jing NN; Huang ZJ
    Pharmacogenet Genomics; 2013 May; 23(5):251-61. PubMed ID: 23459029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of CYP3A4*18B and CYP3A5*3 polymorphism with cyclosporine-related liver injury in Chinese renal transplant recipients.
    Xin HW; Liu HM; Li YQ; Huang H; Zhang L; Yu AR; Wu XC
    Int J Clin Pharmacol Ther; 2014 Jun; 52(6):497-503. PubMed ID: 24691060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes.
    Hesselink DA; van Gelder T; van Schaik RH; Balk AH; van der Heiden IP; van Dam T; van der Werf M; Weimar W; Mathot RA
    Clin Pharmacol Ther; 2004 Dec; 76(6):545-56. PubMed ID: 15592326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of the CYP3A4*1G polymorphism and its combination with CYP3A5 genotypes on tacrolimus pharmacokinetics in renal transplant patients.
    Miura M; Satoh S; Kagaya H; Saito M; Numakura K; Tsuchiya N; Habuchi T
    Pharmacogenomics; 2011 Jul; 12(7):977-84. PubMed ID: 21635144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching Immunosuppression From Cyclosporine to Tacrolimus in Kidney Transplant Recipients Based on CYP3A5 Genotyping.
    Wang X; Yang Y; Liu Z; Xiao C; Gao L; Zhang W; Zhang W; Wang Z
    Ther Drug Monit; 2019 Feb; 41(1):97-101. PubMed ID: 30520827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.